^
Association details:
| Biomarker: | PCM1-PDGFRB fusion |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib
Published date:
05/14/2019
Excerpt:
...we report a novel case of a patient harboring a t(5;8)(q33;p22) translocation, resulting in the PCM1/PDGFRB fusion….After 1 year of treatment with imatinib, the patient achieves hematological and molecular remission….We present an attractive strategy to identify novel and/or cryptic fusions, which will be relevant for clinicians dealing with the diagnosis of the patients with myelodysplastic syndrome/myeloproliferative diseases.
DOI:
https://doi.org/10.1159/000497348
